AP2379A - Imidazole compounds for the treatment of neurodegenerative disorders. - Google Patents

Imidazole compounds for the treatment of neurodegenerative disorders.

Info

Publication number: AP2379A
Authority: AP; ARIPO
Prior art keywords: treatment; neurodegenerative disorders; imidazole compounds; imidazole; compounds
Prior art date: 2004-03-23

Application number

AP2006003727A

Other languages

English (en)

Other versions

AP2006003727A0 (en

Inventor

Michael Aaron Brodney

Karen Jean Coffman

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-23

Filing date

2005-03-11

Publication date

2012-03-08

2005-03-11 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-10-31 Publication of AP2006003727A0 publication Critical patent/AP2006003727A0/xx

2012-03-08 Application granted granted Critical

2012-03-08 Publication of AP2379A publication Critical patent/AP2379A/xx

Links

150000002460 imidazoles Chemical class 0.000 title 1
208000015122 neurodegenerative disease Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AP2006003727A 2004-03-23 2005-03-11 Imidazole compounds for the treatment of neurodegenerative disorders. AP2379A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55562304P	2004-03-23	2004-03-23
PCT/IB2005/000659 WO2005092864A1 (en)	2004-03-23	2005-03-11	Imidazole compounds for the treatment of neurodegenerative disorders

Publications (2)

Publication Number	Publication Date
AP2006003727A0 AP2006003727A0 (en)	2006-10-31
AP2379A true AP2379A (en)	2012-03-08

Family

ID=34961257

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2006003727A AP2379A (en)	2004-03-23	2005-03-11	Imidazole compounds for the treatment of neurodegenerative disorders.

Country Status (42)

Country	Link
US (3)	US7342118B2 (is)
EP (1)	EP1730119B1 (is)
JP (2)	JP4054845B2 (is)
KR (1)	KR100814599B1 (is)
CN (1)	CN1934091B (is)
AP (1)	AP2379A (is)
AR (1)	AR049875A1 (is)
AT (1)	ATE399155T1 (is)
AU (1)	AU2005225635B2 (is)
BR (1)	BRPI0509069B8 (is)
CA (1)	CA2560580C (is)
CR (1)	CR8644A (is)
CY (1)	CY1108347T1 (is)
DE (1)	DE602005007717D1 (is)
DK (1)	DK1730119T3 (is)
DO (1)	DOP2005000040A (is)
EA (1)	EA011689B1 (is)
EC (1)	ECSP066879A (is)
ES (1)	ES2308441T3 (is)
GE (1)	GEP20084420B (is)
GT (1)	GT200500060A (is)
HN (1)	HN2005000115A (is)
HR (1)	HRP20080375T3 (is)
IL (1)	IL177594A0 (is)
IS (1)	IS8550A (is)
MA (1)	MA28481B1 (is)
NL (1)	NL1028598C2 (is)
NO (1)	NO338263B1 (is)
NZ (1)	NZ549331A (is)
PA (1)	PA8627201A1 (is)
PE (1)	PE20051155A1 (is)
PL (1)	PL1730119T3 (is)
PT (1)	PT1730119E (is)
RS (1)	RS50595B (is)
SI (1)	SI1730119T1 (is)
SV (1)	SV2006002055A (is)
TN (1)	TNSN06300A1 (is)
TW (1)	TWI372146B (is)
UA (1)	UA83899C2 (is)
UY (1)	UY28817A1 (is)
WO (1)	WO2005092864A1 (is)
ZA (1)	ZA200606957B (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP2379A (en)	2004-03-23	2012-03-08	Pfizer Prod Inc	Imidazole compounds for the treatment of neurodegenerative disorders.
EP1940802A2 (en)	2005-09-22	2008-07-09	Pfizer Products Inc.	Imidazole compounds for the treatment of neurological disorders
AU2007207743B2 (en)	2006-01-18	2010-07-08	Amgen Inc.	Thiazole compounds as protein kinase B (PKB) inhibitors
DE102006048042A1 (de) *	2006-10-11	2008-04-17	Bayer Healthcare Ag	Acylaminoimidazole und Acylaminothiazole
US8779002B2 (en) *	2007-10-15	2014-07-15	Salk Institute For Biological Studies	Methods for treating a variety of diseases and conditions, and compounds useful therefor
WO2009093463A1 (ja) *	2008-01-23	2009-07-30	Taiho Pharmaceutical Co., Ltd.	神経細胞死抑制剤
EP2398771B1 (en)	2009-02-18	2015-07-29	Boehringer Ingelheim International GmbH	Heterocyclic compounds which modulate the cb2 receptor
WO2010100606A1 (en) *	2009-03-03	2010-09-10	Pfizer Inc.	Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
US8299103B2 (en) *	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
EP2523936A1 (en)	2010-01-15	2012-11-21	Boehringer Ingelheim International GmbH	Compounds which modulate the cb2 receptor
WO2012012307A1 (en)	2010-07-22	2012-01-26	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the cb2 rece
RU2465273C2 (ru) *	2010-08-31	2012-10-27	Общество С Ограниченной Ответственностью "Биофарм-Меморейн"	ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
AU2012321345B2 (en)	2011-10-03	2016-03-17	The University Of Utah Research Foundation	Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
WO2015092614A1 (en)	2013-12-20	2015-06-25	Pfizer Inc.	Activating notch alterations in breast cancer
KR102000382B1 (ko)	2015-02-03	2019-07-15	화이자 인코포레이티드	신규 시클로프로파벤조푸라닐 피리도피라진디온
CA2990564A1 (en)	2015-06-22	2016-12-29	Sumitomo Dainippon Pharma Co., Ltd.	Bicyclic heterocyclic amide derivative
AU2016284398C1 (en)	2015-06-22	2021-01-07	Sumitomo Dainippon Pharma Co., Ltd.	1,4-disubstituted imidazole derivative
JP6896701B2 (ja)	2016-02-26	2021-06-30	大日本住友製薬株式会社	イミダゾリルアミド誘導体
CN120661674A (zh)	2016-03-15	2025-09-19	奥莱松基因组股份有限公司	用于治疗实体瘤的lsd1抑制剂的组合
EP3615055A1 (en)	2017-04-28	2020-03-04	Novartis AG	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en)	2017-04-28	2020-03-04	Novartis AG	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
PE20210320A1 (es)	2018-06-01	2021-02-16	Novartis Ag	Moleculas de union contra bcma y usos de las mismas
EP3843735A1 (en) *	2018-08-27	2021-07-07	Universiteit Maastricht	Selective presenilin-2 gamma-secretase inhibitors
AU2020307471A1 (en)	2019-06-24	2022-01-27	Novartis Ag	Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
US11884634B2 (en)	2019-08-09	2024-01-30	Pfizer Inc.	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
KR102772889B1 (ko) *	2019-08-09	2025-02-26	화이자 인코포레이티드	(s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도
ES3055762T3 (en)	2019-08-09	2026-02-16	Pfizer	Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
KR102782229B1 (ko) *	2019-10-02	2025-03-20	(주)카이노스메드	N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물
JP2023524854A (ja)	2020-05-13	2023-06-13	ファイザー・インク	がんを処置するための方法、治療、および使用
KR20230069181A (ko)	2020-09-14	2023-05-18	화이자 인코포레이티드	암 치료를 위한 방법, 요법 및 용도
EP4008324A1 (en)	2020-12-07	2022-06-08	Cellestia Biotech AG	Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
EP4255409A1 (en)	2020-12-07	2023-10-11	Cellestia Biotech AG	Pharmaceutical combinations for treating cancer
TW202313020A (zh)	2021-06-02	2023-04-01	瑞士商西萊絲蒂亞生物科技股份有限公司	自體免疫及發炎性疾病的治療方法
MX2024002590A (es)	2021-09-01	2024-03-22	Springworks Therapeutics Inc	Sintesis de nirogacestat.
US11504354B1 (en) *	2021-09-08	2022-11-22	SpringWorks Therapeutics Inc..	Chlorinated tetralin compounds and pharmaceutical compositions
WO2023079132A1 (en)	2021-11-08	2023-05-11	Cellestia Biotech Ag	Pharmaceutical combinations for treating cancer
EP4436958A1 (en) *	2021-11-23	2024-10-02	Teva Pharmaceuticals International GmbH	Solid state forms of nirogacestat salts
EP4223292A1 (en)	2022-02-07	2023-08-09	Cellestia Biotech AG	Pharmaceutical combinations for treating cancer
WO2023174390A1 (zh) *	2022-03-17	2023-09-21	苏州科睿思制药有限公司	尼罗司他二氢溴酸盐的晶型及其制备方法和用途
US12036207B2 (en)	2022-05-20	2024-07-16	Springworks Therapeutics, Inc.	Treatments with nirogacestat
IL316750A (en)	2022-05-20	2025-01-01	Springworks Therapeutics Inc	Treatments with Nirogesstat
US12138246B2 (en)	2022-05-20	2024-11-12	Springworks Therapeutics, Inc.	Treatments with nirogacestat
US11951096B2 (en)	2022-05-20	2024-04-09	Springworks Therapeutics, Inc.	Treatments with nirogacestat
US12667555B2 (en)	2022-05-20	2026-06-30	Springworks Therapeutics, Inc.	Treatment of ovarian cancer with nirogacestat
WO2026018210A1 (en)	2024-07-19	2026-01-22	Assia Chemical Industries Ltd.	Solid state forms of nirogacestat dihydrochloride salt
CN119930523B (zh) *	2025-01-22	2026-01-02	上海皓元医药股份有限公司	一种硝加司他中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000049037A1 (en) *	1999-02-19	2000-08-24	Eli Lilly And Company	Growth hormone secretagogues
WO2002010141A1 (en) *	2000-07-31	2002-02-07	Pfizer Products Inc.	Imidazole derivatives

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US50314A (en) *		1865-10-03		Improvement in telegraph-cables
US4512A (en) *		1846-05-09		Smut-machine
DE1236426B (de) *	1960-08-25	1967-03-09	Dolomitwerke Gmbh	Verfahren zur Wasseraufbereitung
US5401851A (en)	1992-06-03	1995-03-28	Eli Lilly And Company	Angiotensin II antagonists
JPH07101958A (ja)	1992-10-16	1995-04-18	Takeda Chem Ind Ltd	セフェム化合物、その製造法および抗菌組成物
DE19629816A1 (de)	1996-07-24	1998-01-29	Hoechst Ag	Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en)	1997-08-19	2000-04-18	Lilly Co Eli	Growth hormone secretagogues.
US6329342B1 (en)	1997-08-19	2001-12-11	Eli Lilly And Company	Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en)	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
US6639076B1 (en)	1998-08-18	2003-10-28	Eli Lilly And Company	Growth hormone secretagogues
US6828331B1 (en)	1999-02-19	2004-12-07	Eli Lilly And Company	Growth hormone secretagogues
US6323315B1 (en)	1999-09-10	2001-11-27	Basf Aktiengesellschaft	Dolastatin peptides
DE10019755A1 (de)	2000-04-20	2001-11-08	Bayer Ag	Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
EP1289526A4 (en)	2000-05-30	2005-03-16	Merck & Co Inc	MELANOCORTIN RECEPTOR AGONISTS
JP2002059707A (ja) *	2000-08-23	2002-02-26	Bridgestone Corp	空気入りタイヤ及び空気入りタイヤの製造方法
WO2002040445A1 (en)	2000-11-17	2002-05-23	Novo Nordisk A/S	Glucagon antagonists/inverse agonists
TW200301698A (en)	2001-12-21	2003-07-16	Bristol Myers Squibb Co	Acridone inhibitors of IMPDH enzyme
KR101018318B1 (ko)	2001-12-21	2011-03-04	노보 노르디스크 에이/에스	Ｇｋ 활성제로서의 아미드 유도체
ES2616539T3 (es)	2002-06-05	2017-06-13	Bristol-Myers Squibb Company	Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
OA12937A (en)	2002-10-09	2006-10-13	Pfizer Prod Inc	Thiazole compounds for the treatment of neurodegenerative disorders.
JP2006504725A (ja)	2002-10-09	2006-02-09	ファイザー・プロダクツ・インク	神経変性障害治療用ピラゾール化合物
JP2006182648A (ja) *	2003-04-08	2006-07-13	Dai Ichi Seiyaku Co Ltd	７員複素環誘導体
MXPA05012196A (es)	2003-05-12	2006-02-08	Pfizer Prod Inc	Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
EP1654260A4 (en)	2003-08-01	2008-09-24	Pfizer Prod Inc	6-LOW HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
MXPA06001480A (es)	2003-08-06	2006-05-15	Pfizer Prod Inc	Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos.
BRPI0413709A (pt)	2003-08-21	2006-10-17	Pfizer Prod Inc	compostos para o tratamento de distúrbios neurodegenerativos
US7348968B2 (en) *	2003-12-02	2008-03-25	Sony Corporation	Wireless force feedback input device
GB0329275D0 (en)	2003-12-18	2004-01-21	Merck Sharp & Dohme	Therapeutic treatment
AP2379A (en)	2004-03-23	2012-03-08	Pfizer Prod Inc	Imidazole compounds for the treatment of neurodegenerative disorders.
US7232820B2 (en)	2004-04-01	2007-06-19	Pfizer Inc	Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en)	2004-04-01	2008-06-10	Pfizer Inc.	Thiazole-amine compounds for the treatment of neurodegenerative disorders
US20050222227A1 (en)	2004-04-01	2005-10-06	Pfizer Inc	Oxazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en)	2004-04-01	2007-05-22	Pfizer Inc	Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7309709B2 (en)	2004-04-01	2007-12-18	Pfizer Inc.	Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
US7163942B2 (en)	2004-04-01	2007-01-16	Pfizer Inc.	Sulfonamide compounds for the treatment of neurodegenerative disorders
EP1940802A2 (en) *	2005-09-22	2008-07-09	Pfizer Products Inc.	Imidazole compounds for the treatment of neurological disorders

2005
- 2005-03-11 AP AP2006003727A patent/AP2379A/xx active
- 2005-03-11 AU AU2005225635A patent/AU2005225635B2/en not_active Expired
- 2005-03-11 DE DE602005007717T patent/DE602005007717D1/de not_active Expired - Lifetime
- 2005-03-11 KR KR1020067019625A patent/KR100814599B1/ko not_active Expired - Lifetime
- 2005-03-11 HR HR20080375T patent/HRP20080375T3/xx unknown
- 2005-03-11 UA UAA200610159A patent/UA83899C2/uk unknown
- 2005-03-11 WO PCT/IB2005/000659 patent/WO2005092864A1/en not_active Ceased
- 2005-03-11 AT AT05708746T patent/ATE399155T1/de active
- 2005-03-11 GE GEAP20059630A patent/GEP20084420B/en unknown
- 2005-03-11 PL PL05708746T patent/PL1730119T3/pl unknown
- 2005-03-11 ES ES05708746T patent/ES2308441T3/es not_active Expired - Lifetime
- 2005-03-11 NZ NZ549331A patent/NZ549331A/en not_active IP Right Cessation
- 2005-03-11 RS RSP-2008/0351A patent/RS50595B/sr unknown
- 2005-03-11 EA EA200601494A patent/EA011689B1/ru not_active IP Right Cessation
- 2005-03-11 CA CA002560580A patent/CA2560580C/en not_active Expired - Lifetime
- 2005-03-11 JP JP2007504496A patent/JP4054845B2/ja not_active Expired - Lifetime
- 2005-03-11 EP EP05708746A patent/EP1730119B1/en not_active Expired - Lifetime
- 2005-03-11 SI SI200530339T patent/SI1730119T1/sl unknown
- 2005-03-11 BR BRPI0509069A patent/BRPI0509069B8/pt not_active IP Right Cessation
- 2005-03-11 PT PT05708746T patent/PT1730119E/pt unknown
- 2005-03-11 DK DK05708746T patent/DK1730119T3/da active
- 2005-03-11 US US11/078,898 patent/US7342118B2/en not_active Expired - Lifetime
- 2005-03-11 CN CN2005800093217A patent/CN1934091B/zh not_active Expired - Lifetime
- 2005-03-18 SV SV2005002055A patent/SV2006002055A/es unknown
- 2005-03-18 PE PE2005000313A patent/PE20051155A1/es not_active Application Discontinuation
- 2005-03-18 HN HN2005000115A patent/HN2005000115A/es unknown
- 2005-03-18 TW TW094108466A patent/TWI372146B/zh not_active IP Right Cessation
- 2005-03-21 GT GT200500060A patent/GT200500060A/es unknown
- 2005-03-21 DO DO2005000040A patent/DOP2005000040A/es unknown
- 2005-03-22 AR ARP050101116A patent/AR049875A1/es not_active Application Discontinuation
- 2005-03-22 NL NL1028598A patent/NL1028598C2/nl not_active IP Right Cessation
- 2005-03-22 UY UY28817A patent/UY28817A1/es not_active Application Discontinuation
- 2005-03-23 PA PA20058627201A patent/PA8627201A1/es unknown
2006
- 2006-08-21 IL IL177594A patent/IL177594A0/en active IP Right Grant
- 2006-08-21 ZA ZA2006/06957A patent/ZA200606957B/en unknown
- 2006-09-21 CR CR8644A patent/CR8644A/es unknown
- 2006-09-22 MA MA29336A patent/MA28481B1/fr unknown
- 2006-09-22 TN TNP2006000300A patent/TNSN06300A1/fr unknown
- 2006-09-22 EC EC2006006879A patent/ECSP066879A/es unknown
- 2006-10-09 IS IS8550A patent/IS8550A/is unknown
- 2006-10-18 NO NO20064726A patent/NO338263B1/no unknown
2007
- 2007-06-13 JP JP2007156459A patent/JP2007291123A/ja active Pending
2008
- 2008-01-09 US US11/971,272 patent/US7795447B2/en active Active
- 2008-09-17 CY CY20081101001T patent/CY1108347T1/el unknown
2010
- 2010-03-12 US US12/723,204 patent/US7951958B2/en not_active Expired - Lifetime

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000049037A1 (en) *	1999-02-19	2000-08-24	Eli Lilly And Company	Growth hormone secretagogues
WO2002010141A1 (en) *	2000-07-31	2002-02-07	Pfizer Products Inc.	Imidazole derivatives

Also Published As

Publication number	Publication date
ES2308441T3 (es)	2008-12-01
WO2005092864A1 (en)	2005-10-06
AR049875A1 (es)	2006-09-13
BRPI0509069B8 (pt)	2021-05-25
SI1730119T1 (sl)	2008-10-31
CN1934091B (zh)	2012-02-08
DK1730119T3 (da)	2008-08-11
EP1730119B1 (en)	2008-06-25
AP2006003727A0 (en)	2006-10-31
HK1099756A1 (en)	2007-08-24
US7951958B2 (en)	2011-05-31
UY28817A1 (es)	2005-10-31
JP2007291123A (ja)	2007-11-08
NZ549331A (en)	2010-08-27
US20080227781A1 (en)	2008-09-18
US20100168107A1 (en)	2010-07-01
TNSN06300A1 (fr)	2007-12-03
EP1730119A1 (en)	2006-12-13
HRP20080375T3 (hr)	2008-09-30
CN1934091A (zh)	2007-03-21
GEP20084420B (en)	2008-07-10
HN2005000115A (es)	2009-04-20
IL177594A0 (en)	2006-12-10
US7342118B2 (en)	2008-03-11
ZA200606957B (en)	2008-03-26
CA2560580C (en)	2008-12-23
AU2005225635A1 (en)	2005-10-06
DE602005007717D1 (de)	2008-08-07
TWI372146B (en)	2012-09-11
BRPI0509069B1 (pt)	2019-07-02
AU2005225635B2 (en)	2010-06-24
PT1730119E (pt)	2008-09-02
SV2006002055A (es)	2006-05-09
CR8644A (es)	2006-11-01
CY1108347T1 (el)	2014-02-12
BRPI0509069A (pt)	2007-08-21
CA2560580A1 (en)	2005-10-06
DOP2005000040A (es)	2005-10-21
KR100814599B1 (ko)	2008-03-17
US20050215610A1 (en)	2005-09-29
MA28481B1 (fr)	2007-03-01
PE20051155A1 (es)	2006-01-28
ATE399155T1 (de)	2008-07-15
ECSP066879A (es)	2006-11-24
GT200500060A (es)	2005-10-24
KR20060123651A (ko)	2006-12-01
PA8627201A1 (es)	2005-12-23
RS50595B (sr)	2010-05-07
PL1730119T3 (pl)	2008-10-31
NO20064726L (no)	2006-12-22
US7795447B2 (en)	2010-09-14
IS8550A (is)	2006-10-09
EA011689B1 (ru)	2009-04-28
JP4054845B2 (ja)	2008-03-05
EA200601494A1 (ru)	2007-02-27
NL1028598C2 (nl)	2006-01-03
NO338263B1 (no)	2016-08-08
JP2007530525A (ja)	2007-11-01
NL1028598A1 (nl)	2005-09-26
TW200539875A (en)	2005-12-16
UA83899C2 (uk)	2008-08-26

Publication	Publication Date	Title
TWI372146B (en)	2012-09-11	Imidazole compounds for the treatment of neurodegenerative disorders
IL208607A0 (en)	2010-12-30	Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL185016A0 (en)	2007-12-03	Compounds for the treatment of proliferative disorders
ZA200803440B (en)	2009-03-25	Compounds for the treatment of metabolic disorders
IL180736A0 (en)	2007-06-03	Hydantoin derivatives for the treatment of inflammatory disorders
IL192691A0 (en)	2009-02-11	Hydantoin compounds for the treatment of inflammatory disorders
IL178648A0 (en)	2007-02-11	Substituted morpholine compounds for the treatment of central nervous system disorders
EP1654260A4 (en)	2008-09-24	6-LOW HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
ZA200805159B (en)	2009-03-25	Imidazole derivatives for the treatment of gastrointestinal disorders
EP1658072A4 (en)	2009-03-25	Compounds for the Treatment of Neurodegenerative Diseases
IL187439A0 (en)	2008-02-09	Compounds useful for treating neurodegenerative disorders
IL189524A0 (en)	2008-08-07	Imidazole compounds for the treatment of neurological disorders
NL1030418A1 (nl)	2006-05-16	Azabenzoxazolen voor de behandeling van CZS-stoornissen.
AP2006003729A0 (en)	2006-10-31	Sulfonamide compounds for the treatment of neurodegenerative disorders
EP1653952A4 (en)	2007-04-04	OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
IL189853A0 (en)	2008-11-03	Treatment of neurodegenerative disorders
EP1734957A4 (en)	2009-06-17	THIAZOLE SULFAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
GB2432586B (en)	2010-01-13	Treatment of neurodegenerative disorders
ZA200606780B (en)	2008-08-27	Compounds for the treatment of diseases
GB0428081D0 (en)	2005-01-26	Sulphur-linked imidazole compounds for the treatment of HIV
HK1124600A (en)	2009-07-17	Imidazole derivatives for the treatment of gastrointestinal disorders
HK1119685A (en)	2009-03-13	Compounds for the treatment of inflammatory disorders
AP2005003270A0 (en)	2005-03-31	Composition for the treatment of humans.
GB0420867D0 (en)	2004-10-20	Compounds for the treatment of diseases
GB0425073D0 (en)	2004-12-15	Compounds for the treatment of diseases